Salvinorin A Stats & Data

Rationale: Core pharmacology. Salvinorin A is a potent and selective kappa-opioid receptor (KOR) agonist with negligible activity at 5-HT2A, which explains its non-classical psychedelic profile and frequent dysphoria/derealization compared with serotonergic psychedelics. This also justifies removing the prior unsubstantiated fluoxetine (SSRI) ‘CNS depressant’ interaction. Sources include Roth et al. and EMCDDA/EUDA profile. Rationale: Route-dependent activity. Swallowed (gastric) dosing is largely inactive due to first-pass inactivation; psychoactivity depends on buccal/sublingual absorption or inhalation. This underpins replacing the prior ‘oral’ microgram table with ‘sublingual’ and ‘vaporized’ routes and warning that simply swallowing is ineffective. Rationale: Microgram potency and measurement risk. Effective vaporized doses often begin near 200–500 µg; ‘full’ effects are commonly reported at 0.6–1.0 mg with steep dose–response. Microgram-level dosing requires a lab-grade balance or pre-measured materials to reduce the risk of accidental overwhelming experiences. Rationale: Onset and duration. Vaporized salvinorin A has onset within 20–60 s, very brief peak (≈1–5 min), and main effects resolve within 5–20 min; sublingual/tincture routes are slower-on, longer-lasting (up to ~2 h). This informs planning, sitter use, and driving restrictions post-episode. Rationale: Safety/sitter and environment. Profound disorientation, amnesia, ataxia, and wandering can occur; a sober sitter and hazard-free setting (seated/lying, away from glass, fire, edges) reduce injuries. Avoid smoking/vaporizing while standing; do not operate vehicles until fully baseline. Rationale: Interactions. • Antagonists: Competitive opioid antagonists (naltrexone, naloxone) block salvinorin A’s effects; this is not dangerous but makes dosing unpredictable if on therapy. • CNS depressants: DrugBank lists numerous sedative class interactions raising CNS depression risk; combining with alcohol, benzos, or opioids likely increases accident risk during incapacitating episodes. • MAOIs: TripSit notes anecdotal potentiation; treat as unknown/synergistic and avoid. Rationale: Tolerance. Community and summary sources suggest minimal or no rapid tolerance; some report a subjective ‘reverse tolerance’ or sensitization with experience, but this remains anecdotal. Thus we keep formal tolerance ‘unknown’ and advise not to escalate doses within a session. Rationale: Pharmacokinetics. Human half-life is not well defined; primate PET shows rapid brain clearance (~8 min), and rodent studies suggest a short systemic t1/2 (~75 min). This supports the brief intense window and the advice to plan the environment before dosing rather than redosing to ‘chase’ effects. Rationale: Solubility/formulation. EMCDDA and Erowid note salvinorin A is insoluble in water but soluble in organic solvents; sublingual ethanol tinctures are used, with onset 5–10 min. This underlies specifying ‘sublingual’ rather than general ‘oral’ and cautioning that ethanol solutions are typical; avoid denatured alcohol/DMSO for safety. Rationale: Mental health screening. EMCDDA cautions psychotic disturbances may occur in vulnerable individuals; brief episodes can precipitate longer disturbances. Users with a history of psychosis should avoid. Rationale: Not detected on standard drug tests. Salvinorin A is not included in common SAMHSA-5 panels, though specialized testing is possible. This is relevant for informed consent, not encouragement.